Intellia Therapeutics Stock Forecast

Stock Price Forecast

According to 20 analysts polled by S&P Global, Intellia Therapeutics stock has a consensus rating of "Buy" and an average price target of $22.78. The average 1-year stock price forecast is 104.12% higher than the current stock price, while the lowest is $8.00 (-28.32%) and the highest is $61 (+446.59%).

Price Target: $22.78 (+104.12%)

Analyst Consensus: Buy

Price Target

Chart

Target	Low	Average	Median	High
Price	$8.00	$22.78	$15.5	$61
Change	-28.32%	+104.12%	+38.89%	+446.59%

Analyst Ratings

The average analyst rating for Intellia Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Chart

Rating	Jun '26	Jul '26	Aug '26	Sep '26	Oct '26	Nov '26
Strong Buy	10	8	9	9	9	9
Buy	2	1	1	1	1	1
Hold	8	7	6	6	6	6
Sell	1	1	1	1	2	2
Strong Sell	1	2	2	2	2	2
Total	22	19	19	19	20	20

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Whitney Ijem Canaccord Genuity	Canaccord Genuity	Buy Maintains $49	Buy	Maintains	$49	+339.07%	Nov 9, 2026
Brian Cheng J.P. Morgan	J.P. Morgan	Sell Reiterates $8 → $9	Sell	Reiterates	$8 → $9	-19.35%	Nov 9, 2026
Debanjana Chatterjee JonesTrading	JonesTrading	Buy Maintains $29 → $27	Buy	Maintains	$29 → $27	+141.94%	Nov 6, 2026
Terence Flynn Morgan Stanley	Morgan Stanley	Hold Maintains $15	Hold	Maintains	$15	+34.41%	Nov 6, 2026
Luca Issi RBC Capital	RBC Capital	Hold Maintains $15	Hold	Maintains	$15	+34.41%	Nov 6, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

43.72M

from 67.67M

-35.40%

from 67.67M

Revenue Next Year

143.97M

from 43.72M

229.31%

from 43.72M

EPS This Year

-3.26

from -3.81

EPS Next Year

-2.63

from -3.26

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	33.05M	52.12M	36.28M	57.88M	67.67M	43.72M
Revenue Growth	-43.01%	57.69%	-30.40%	59.55%	16.92%	-35.40%
Operating Income	-267.85M	-458.16M	-515.29M	-534.26M	-440.99M	-445.37M
Net Income	-267.89M	-474.19M	-481.19M	-519.02M	-412.69M	-437.40M
EPS	-	-	-	-	-3.81	-3.26
Free Cash Flow	-	-	-	-	-395.87M	-439.88M
No. Analysts	-	-	-	-	-	16

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Chart

Revenue	2026	2027	2028
High	100.0M
Avg	43.7M
Low	36.9M

Revenue Growth

Chart

Revenue Growth	2026	2027	2028
High	47.8%
Avg	-35.4%
Low	-45.5%

EPS Forecast

Chart

EPS	2026	2027	2028
High	-2.71
Avg	-3.26
Low	-3.60

EPS Growth

Chart

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-